A detailed history of Boston Common Asset Management, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Boston Common Asset Management, LLC holds 55,110 shares of AZN stock, worth $3.67 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
55,110
Previous 62,965 12.48%
Holding current value
$3.67 Million
Previous $4.91 Million 26.42%
% of portfolio
0.21%
Previous 0.13%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 15, 2025

SELL
$63.2 - $79.58 $496,436 - $625,100
-7,855 Reduced 12.48%
55,110 $3.61 Million
Q3 2024

Oct 09, 2024

SELL
$76.67 - $87.62 $250,174 - $285,904
-3,263 Reduced 4.93%
62,965 $4.91 Million
Q2 2024

Jul 08, 2024

SELL
$66.81 - $80.83 $165,287 - $199,973
-2,474 Reduced 3.6%
66,228 $5.17 Million
Q1 2024

Apr 11, 2024

BUY
$61.03 - $69.57 $71,832 - $81,883
1,177 Added 1.74%
68,702 $4.66 Million
Q4 2023

Jan 09, 2024

SELL
$61.89 - $69.28 $376,848 - $421,845
-6,089 Reduced 8.27%
67,525 $4.55 Million
Q3 2023

Oct 11, 2023

SELL
$64.85 - $71.7 $140,335 - $155,158
-2,164 Reduced 2.86%
73,614 $4.99 Million
Q2 2023

Jul 24, 2023

BUY
$69.91 - $75.81 $144,993 - $157,229
2,074 Added 2.81%
75,778 $5.42 Million
Q1 2023

May 17, 2023

BUY
$63.15 - $71.6 $461,815 - $523,610
7,313 Added 11.02%
73,704 $5.12 Million
Q4 2022

Jan 26, 2023

BUY
$54.21 - $70.44 $724,733 - $941,712
13,369 Added 25.21%
66,391 $4.5 Million
Q3 2022

Oct 20, 2022

BUY
$53.02 - $135.75 $761,579 - $1.95 Million
14,364 Added 37.16%
53,022 $2.91 Million
Q2 2022

Aug 10, 2022

BUY
$59.26 - $71.14 $2.29 Million - $2.75 Million
38,658 New
38,658 $2.55 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $206B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Boston Common Asset Management, LLC Portfolio

Follow Boston Common Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.